Novel therapeutics and future directions for refractory immune thrombocytopenia
British Journal of Haematology · 2023-10 · 203 (1) · 65-78
DOI: 10.1111/bjh.19078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 21.09.2023. Verfasst von Hanny Al-Samkari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20 000 people. While most patients with ITP are successfully managed with the current set of standard and approved therapeutics, patients who cannot be adequately managed with these therapies, considered to have refractory ITP, are not uncommon. Therefore, there remains an ongoing need for novel therapeutics and drug development in ITP. Several agents exploiting novel targets and mechanisms in ITP are presently under clinical development, with trials primarily recruiting heavily pretreated patients and those with otherwise refractory disease. Such agents include the neonatal Fc receptor antagonist efgartigimod, the Bruton tyrosine kinase inhibitor rilzabrutinib, the complement inhibitors sutimlimab and iptacopan and anti‐CD38 monoclonal antibodies such as daratumumab and mezagitamab, among others. Each of these agents exploits therapeutic targets or other aspects of ITP pathophysiology currently not targeted by the existing approved agents (thrombopoietin receptor agonists and fostamatinib). This manuscript offers an in‐depth review of the current available data for novel therapeutics in ITP presently undergoing phase 2 or 3 studies in patients with heavily pretreated or refractory ITP. It additionally highlights the future directions for drug development in refractory ITP, including discussion of innovative clinical trial designs, health‐related quality of life as an indispensable clinical trial end‐point and balancing potential toxicities of drugs with their potential benefits in a bleeding disorder in which few patients suffer life‐threatening bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID-Profile: Hanny Al-Samkari, Ellis J Neufeld
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Al-Samkari, H., & Neufeld, E. J. (2023). Novel therapeutics and future directions for refractory immune thrombocytopenia. British Journal of Haematology, 203(1), 65-78. https://doi.org/10.1111/bjh.19078
Vancouver
Al-Samkari H, Neufeld EJ. Novel therapeutics and future directions for refractory immune thrombocytopenia. British Journal of Haematology. 2023;203(1):65-78. doi:10.1111/bjh.19078
BibTeX
@article{AlSamkari2023,
author = {Al-Samkari, Hanny and Neufeld, Ellis J},
title = {Novel therapeutics and future directions for refractory immune thrombocytopenia},
journal = {British Journal of Haematology},
year = {2023},
volume = {203},
number = {1},
pages = {65--78},
doi = {10.1111/bjh.19078}
}
EUVIMED